Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76


Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial.

Boyle RJ, Pedroletti C, Wickman M, Bjermer L, Valovirta E, Dahl R, Von Berg A, Zetterström O, Warner JO; 4A Study Group.

Thorax. 2012 Mar;67(3):215-21. doi: 10.1136/thoraxjnl-2011-200665. Epub 2011 Nov 30.


Clinical effects of purified air administered to the breathing zone in allergic asthma: A double-blind randomized cross-over trial.

Pedroletti C, Millinger E, Dahlén B, Söderman P, Zetterström O.

Respir Med. 2009 Sep;103(9):1313-9. doi: 10.1016/j.rmed.2009.03.020. Epub 2009 May 13.


Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.

Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H.

Pediatrics. 2004 Apr;113(4):e308-12.


Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group.

Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei LX, Seidenberg BC, Reiss TF.

Ann Intern Med. 1999 Mar 16;130(6):487-95.


Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.

Respir Med. 2008 Oct;102(10):1371-8. doi: 10.1016/j.rmed.2008.06.002. Epub 2008 Jul 26.


Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.

Allergy. 2005 Mar;60(3):309-16.


Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.

Massanari M, Kianifard F, Zeldin RK, Geba GP.

Allergy Asthma Proc. 2009 Sep-Oct;30(5):534-9. doi: 10.2500/aap.2009.30.3245. Epub 2009 May 22.


Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL.

Pediatrics. 2001 Sep;108(3):E48.


The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner WA.

J Allergy Clin Immunol. 2013 Mar;131(3):866-74. doi: 10.1016/j.jaci.2012.12.1561. Epub 2013 Feb 4.


Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.

O'Connor BJ, Collarini S, Poli G, Brindicci C, Spinola M, Acerbi D, Barnes PJ, Leaker B.

BMC Pulm Med. 2011 Dec 21;11:60. doi: 10.1186/1471-2466-11-60.


Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma.

Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, Rojas R, van Noord JA, Pons M, Gilles L, Leff JA; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group.

Thorax. 2003 Mar;58(3):211-6.


Randomised, double blind, placebo-controlled trial of selenium supplementation in adult asthma.

Shaheen SO, Newson RB, Rayman MP, Wong AP, Tumilty MK, Phillips JM, Potts JF, Kelly FJ, White PT, Burney PG.

Thorax. 2007 Jun;62(6):483-90. Epub 2007 Jan 18.


Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

Items per page

Supplemental Content

Write to the Help Desk